Zhejiang Weixin Biopharmaceutical

Zhejiang Weixin Biopharmaceutical is a clinical-stage Chinese biotechnology company specializing in the development of recombinant protein vaccines. The company's primary focus is its 9-valent Human Papillomavirus (HPV) vaccine, which is currently in Phase 3 clinical trials and aims to provide a high-quality domestic alternative to imported vaccines. Utilizing advanced protein expression technologies, the firm targets significant public health challenges in the infectious disease space. Headquartered in Huzhou, Zhejiang, the company is positioned as a key player in China's rapidly evolving vaccine industry. Its pipeline is designed to address the high demand for cervical cancer prevention and other viral infections.